The CDK inhibitor SNS-032 had previously exerted promising anti-neuroblastoma activity via CDK7 and 9 inhibition. ABCB1 expression was identified as major determinant of SNS-032 resistance. Here, we investigated the role of ABCB1 in acquired SNS-032 resistance. In contrast to ABCB1-expressing UKF-NB-3 sublines resistant to other ABCB1 substrates, SNS-032-adapted UKF-NB-3 (UKF-NB-3 r SNS-032 300nM ) cells remained sensitive to the non-ABCB1 substrate cisplatin and were completely re-sensitized to cytotoxic ABCB1 substrates by ABCB1 inhibition. Moreover, UKF-NB-3rSNS-032 300nM cells remained similarly sensitive to CDK7 and 9 inhibition as UKF-NB-3 cells. In contrast, SHEPrSNS-032 2000nM , the SNS-032-resistant sub-line of the neuroblastoma cell line SHEP, displayed low level SNS-032 resistance also when ABCB1 was inhibited. This discrepancy may be explained by the higher SNS-032 concentrations that were used to establish SHEPrSNS-032 2000nM cells, since SHEP cells intrinsically express ABCB1 and are less sensitive to SNS-032 (IC 50 912 nM) than UKF-NB-3 cells (IC 50 153 nM). In conclusion, we show that ABCB1 expression represents the primary (sometimes exclusive) resistance mechanism in neuroblastoma cells with acquired resistance to SNS-032. Thus, ABCB1 inhibitors may increase the SNS-032 efficacy in ABCB1-expressing cells and prolong or avoid resistance formation.
INTRODUCTION
Neuroblastoma is the most frequent solid extracranial pediatric cancer. About half of the patients are diagnosed with high-risk disease associated with overall survival rates below 50% despite myeloablative therapy and differentiation therapy using retinoids [1, 2] .
SNS-032 (BMS-387032) is a cyclin-dependent kinase 2 (CDK2), 7, and 9 inhibitor under pre-clinical and clinical investigation for a wide range of solid and hematologic malignancies [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] including neuroblastoma [17] [18] [19] . The compound was initially introduced as N-acyl-2-aminothiazole inhibitor of CDK2 [3] . The relevance of CDK2, CDK7, and/ or CDK9 as crucial SNS-032 drug targets differs between different cancer cell types [4, 7-9, 12, 19] . We recently showed that therapeutic SNS-032 concentrations exerted antineuroblastoma effects in a panel of 109 neuroblastoma cell lines (19 parental neuroblastoma cell lines, 90 sublines with acquired resistance to 14 different anti-cancer drugs) and in primary neuroblastoma cells [19] . SNS-032 further inhibited tumor growth in a chemoresistant neuroblastoma xenograft model [19] . Interference with CDK7 and CDK9 appeared to be critical for the antineuroblastoma effects of SNS-032 [19] .
SNS-032 had further been speculated to interfere with ABCB1 (also known as P-glycoprotein or MDR1) [20] . Our report (published on the 1st December 2013) Research Paper www.impactjournals.com/oncotarget [19] and another report (published on 23rd December 2013) [21] confirmed this assumption. ABCB1 expression was the dominant SNS-032-resistance mechanism in neuroblastoma cells from a panel of 109 neuroblastoma cell lines [19] . Only ABCB1-expressing neuroblastoma cell lines were insensitive to therapeutically achievable SNS-032 concentrations. In the presence of ABCB1 inhibitors, all 30 ABCB1-expressing neuroblastoma cell lines displayed SNS-032 IC 50 values in the range of therapeutic SNS-032 concentrations [19] .
Here, we established and characterized SNS-032-resistant sub-lines of the MYCN-amplified, ABCB1-negative neuroblastoma cell line UKF-NB-3 (UKF-NB-3 r SNS-032 300nM ) and the non-MYCN-amplified, ABCB1-expressing neuroblastoma cell line SHEP (SHEP r SNS-032 2000nM ) to analyze the role of ABCB1 in neuroblastoma models of acquired SNS-032 resistance.
RESULTS

Enhanced ABCB1 expression in the SNS-032-resistant UKF-NB-3 sub-line UKF-NB-3 r
SNS-032 300nM
UKF-NB-3 cells were adapted to growth in the presence of SNS-032 300 nM by step-wise increase of the SNS-032 concentration. No pre-existing resistant sub-population could be selected by directly applying SNS-032 300 nM. The SNS-032 IC 50 value was four times higher in SNS-032-adapted UKF-NB-3 r SNS-032 300nM cells (606.7 nM) than in UKF-NB-3 cells (152.6 nM). UKF-NB-3 and its SNS-032-resistant sub-line UKF-NB-3 r SNS-032 300nM were characterized by similar doubling times (UKF-NB-3: 26.6 ± 8.2 h, UKF-NB-3 r SNS-032 300nM 32.9 ± 12.8 h) and a similar morphology (Supplementary Figure S1 ). However, UKF-NB-3 r SNS-032 300nM cells displayed elevated ABCB1 levels relative to UKF-NB-3 cells (Figure 1, Supplementary Figure S2) . We had previously shown that SNS-032 is also a substrate of ABCG2 (also known as BCRP) [19] . In contrast, expression of ABCC1 (also known as MRP1), another relevant ABC transporter known to be involved in cancer cell drug resistance in various cancer entities including neuroblastoma [22] , did not influence anti-cancer activity of SNS-032 (Supplementary Figure S3) . We did neither detect increased ABCG2 nor ABCC1 expression in UKF-NB- Figure 3 ; Supplementary Table S1A) .
To further confirm the role of ABCB1 in UKF-NB-3 r SNS-032 300nM cells, we depleted ABCB1 using siRNA. ABCB1 depletion increased SNS-032 sensitivity in UKF-NB-3 r SNS-032 300nM cells. Since no complete suppression of ABCB1 expression was achieved by siRNA, the SNS-032 IC 50 remained higher than in parental UKF-NB-3 cells (Supplementary Table S1B ; Supplementary Figure S4 ). However, the SNS-032 IC 50 value could be reduced in UKF-NB-3 r SNS-032 300nM cells to the level of UKF-NB-3 cells by the use of zosuquidar (Supplementary  Table S1C ), an alternative ABCB1 inhibitor that structurally differs from verapamil [23] .
Moreover, we synthesized a fluorescent SNS-032-BODIPY derivative. Flow cytometry experiments indicated, compared to UKF-NB-3, a reduced accumulation of SNS-032-BODIPY in ABCB1-transduced UKF-NB-3 (UKF-NB-3 ABCB1 ) cells and UKF-NB-3 r SNS-032 300nM cells that could be restored by the use of verapamil (Supplementary Figure S5) . Notably, the differences between SNS-032-BODIPY accumulation in UKF-NB-3 r SNS-032 300nM cells in the absence or presence of verapamil seemed to be small compared to the differences observed in UKF-NB-3 ABCB1 cells. However, this appears to reflect the respective discrepancies in the SNS-032 IC 50 
CDK7 and CDK9 as drug targets in UKF-NB-3 r SNS-032 300nM cells
We had previously shown that SNS-032 reduces the viability of UKF-NB-3 cells via interference with CDK7 and CDK9 and subsequent RNA polymerase II inhibition resulting in depletion of anti-apoptotic proteins with a high turnover rate including Mcl-1, XIAP, and survivin [19] .
In the presence of verapamil 10 µM, SNS-032 300 nM exerted similar effects on RNA polymerase II protein levels, RNA polymerase II phosphorylation at Ser-5 (target of CDK7), RNA polymerase II phosphorylation at Ser-2 (target of CDK9) ( Figure 5A ), RNA polymerase II activity ( Figure 5B), and XIAP, Mcl-1, and survivin protein levels ( Figure 5A ) in UKF-NB-3 r SNS-032 300nM cells as in UKF-NB-3 cells.
Moreover, the relative resistances IC 50 UKF-NB-3 r SNS-032 300nM / IC 50 UKF-NB-3 were ≤ 1.5 for the CDK2, 7, and 9 inhibitor seliciclib (also known as roscovitine or CYC202) [24] , the CDK9 inhibitor LDC000067 [25] , the CDK7 inhibitor BS-181 [26] , and the CDK 1, 2, 4, 6, 7, and 9 inhibitor alvocidib (also known as flavopiridol or HMR-1275) [27] ( Figure 6A ; Supplementary Table S1F) . Finally, UKF-NB-3 r SNS-032 300nM cells were similar sensitive to siRNA-mediated depletion of CDK7 and CDK9 as UKF-NB-3 cells ( Figure 6B , Supplementary Table S1G) . Hence, UKF-NB-3 r SNS-032 300nM cells do not seem to have acquired specific resistance to CDK inhibition. Table S1A ). * P < 0.05 relative to the drug concentration that reduces cell viability by 50% (IC 50 ) in UKF-NB-3 cells. www.impactjournals.com/oncotarget (Supplementary Figure S1) . Adaptation of SHEP cells to SNS-032 resulted in a further increase of the cellular ABCB1 levels but did not affect ABCG2 or ABCC1 expression levels ( Figure 1, Supplementary Figure S2 Figure 8A , Supplementary Table S1I).
Investigation of SHEPrSNS
In the presence of verapamil, SNS-032 600 nM caused maximum RNA polymerase inhibition in SHEP r SNS-032 2000nM cells (32 ± 4% activity relative to non-treated control). This effect was not further enhanced by increasing the SNS-032 concentration to 1200 nM (31 ± 5% activity relative to non-treated control) ( Figure 8B, Supplementary Table S1J ). In contrast to this, combined SHEP cell treatment with SNS-032 600 nM and verapamil reduced RNA polymerase activity to 22 ± 3% relative to untreated control, which was further decreased by combined SNS-032 1200 nM and verapamil treatment to 16 ± 3% ( Figure 8B , Supplementary Table S1J). The positive control actinomycin D 100 ng/mL, which is also an ABCB1 substrate [28] and interferes with RNA polymerase activity through DNA intercalation independently of CDK7 and CDK9 [29, 30] 
DISCUSSION
To study acquired SNS-032 resistance mechanisms, we established two SNS-032-resistant neuroblastoma cell lines. Elevated ABCB1 expression represented, depending on the investigated cell line model, a dominant or even exclusive acquired SNS-032 resistance mechanism. In the clinics, few neuroblastomas appear to express ABCB1 at diagnosis [31] . However, ABCB1 expression might represent an acquired resistance mechanism in neuroblastoma [32] . In addition, ABCB1 expression may be an SNS-032-associated acquired resistance mechanism in neuroblastoma. Drug-adapted cancer cell lines were previously successfully used to identify novel clinically relevant acquired drug resistance mechanisms [33] [34] [35] [36] [37] .
The resistance status of the SNS-032-resistant UKF-NB-3 sub-line UKF-NB-3 r SNS-032 300nM depended exclusively on ABCB1 function. ABCB1 inhibition completely re-sensitized UKF-NB-3 r SNS-032 300nM to SNS-032 to the level of UKF-NB-3 cells. The same observation was made for UKF-NB-3 r SNS-032 300nM cell sensitivity to the ABCB1 substrates doxorubicin, etoposide, and vincristine. UKF-NB-3 r SNS-032 300nM cells displayed cross-resistance to these agents but their sensitivity to these drugs returned to the levels of UKF-NB-3 in the presence of the ABCB1 inhibitor verapamil. Moreover, UKF-NB-3 r SNS-032 300nM cells did not display cross-resistance to the non-ABCB1 substrate cisplatin or the alternative CDK inhibitors seliciclib, LDC000067, BS-181, or alvocidib. Previous results had demonstrated that SNS-032 reduces the viability of UKF-NB-3 cells (and other cancer cells) via interference with CDK7 and CDK9 and subsequent RNA polymerase II inhibition resulting in depletion of anti-apoptotic proteins with a high turnover rate including Mcl-1, XIAP, and survivin [7 ,8, 19] . In the presence of the ABCB1 2000nM resulted in slight but noticeable differences. We had selected the neuroblastoma cell line SHEP as additional model for our study because it differs in two crucial parameters from UKF-NB-3: 1) SHEP cells do not harbor a MYCN 2000nM cells than in SHEP cells when ABCB1 was inhibited. However, both cell lines displayed in the presence of the ABCB1 inhibitor verapamil the same sensitivity to RNA polymerase inhibition by actinomycin D that is also an ABCB1 substrate [28] and interferes with RNA polymerase activity by CDK7-and CDK9-independent mechanisms [29, 30] . These findings are again in contrast to observations in UKF-NB-3 r SNS-032 300nM cells and indicate that SHEP r SNS-032
2000nM cells developed mechanisms to bypass SNS-032-induced CDK7 and 9 inhibition and subsequent RNA polymerase activity but no general resistance to RNA polymerase inhibition. This specific resistance to RNA polymerase inhibition via interference with CDK7 and 9 also confirms CDK7 and 9 as critical drug targets of SNS-032 in neuroblastoma that was previously suggested [19] . Hence, drug-adapted cells can be used to identify and confirm drug mechanisms of action.
A likely explanation for the differences observed between the resistance phenotypes of UKF- It is known that kinase inhibitors designed to interfere with the same or similar targets may substantially differ in their overall pharmacological profiles (with regards to kinase inhibition as well as other structures) [8, 10, [38] [39] [40] [41] [42] . Hence, the lack of cross-resistance may not be too surprising. The inhibitory profiles of the different 300nM to the CDK2, 7, and 9 inhibitor seliciclib, the CDK7 inhibitor LDC000067, the CDK9 inhibitor BS-181, or the CDK 1,2,4,6,7, and 9 inhibitor alvocidib. Numerical values are presented in Supplementary Table S1F. (B) Effects of siRNA-mediated depletion of CDK7, CDK9, or CDK7 and CDK9 on UKF-NB-3 and UKF-NB-3 r SNS-032 300nM cell viability as determined by MTT assay 72 h post-transfection. Non-targeting 'scrambled' siRNA (scr siRNA) served as control. Western blots indicating siRNA-mediated effects on protein levels are presented in Supplementary Figure S6 . Numerical values are presented in Supplementary Table S1G. * P < 0.05 relative to scr siRNA. www.impactjournals.com/oncotarget CDK inhibitors differ with regard to their CDK inhibitory profiles. Seliciclib interferes (in contrast to SNS-032) with CDK5 in addition to CDK2, CDK7, and CDK9 [24, 43] . BS-181 does in contrast to SNS-032 not inhibit CDK9 [26] . LDC000067 was introduced as selective CDK9 inhibitor with negligible affinity to alternative CDKs [25] . Alvocidib is a broad spectrum CDK inhibitor acting on CDKs 1, 2, 4, 6, 7, and 9 [27] .
Notably, cisplatin-resistant (UKF-NB-3 r CDDP 1000 ), doxorubicin-resistant (UKF-NB-3 r DOX 20 ) , and vincristine-resistant (UKF-NB-3 r VCR 10 ) UKF-NB-3 sub-lines remained sensitive to seliciclib, LDC000067, BS-181, and alvocidib (Supplementary Table S1K ) further supporting a possible role of CDKs as drug targets in neuroblastoma including therapy-refractory disease as previously suggested [17] [18] [19] . The alvocidib IC 50 s were below 400 nM. In phase I clinical trials, steady-state plasma alvocidib concentrations > 400 µM were achieved in human patients [44] .
In conclusion, we show that ABCB1 expression represents the predominant resistance mechanism in neuroblastoma cells with acquired resistance to SNS-032. Most strikingly (and in clear contrast to neuroblastoma cell lines with acquired resistance to other anti-cancer agents that are ABCB1 substrates), ABCB1 expression is an exclusive resistance mechanism Table S1H. in UKF-NB-3 r SNS-032 300nM cells and a predominant resistance mechanism in SHEP r SNS-032 2000nM cells. Although selective ABCB1 inhibitors are available [45, 46] , clinical trials were disappointing. Reasons included that ABCB1 transporter inhibition may affect ABCB1-expressing hematopoietic stem cells and the body distribution of drugs due to effects on ABCB1 present on tissue barriers (e.g. the blood-brain-barrier). Also cancer cells may express multiple ABC transporters [45, 46] . However, ABCB1 expression represents the dominant (sometimes exclusive) resistance mechanism to SNS-032 in neuroblastoma. Therefore, ABCB1
inhibitors may be candidates for combination therapy with SNS-032 that increase SNS-032 efficacy through (re)sensitization of ABCB1-expressing cancer cells, possibly reducing resistance formation.
MATERIALS AND METHODS
Drugs
SNS-032, BS-181, and LDC000067 were purchased from Selleck Chemicals via BIOZOL GmbH (Eching, Germany), seliciclib from LC Laboratories (Woburn, 
Synthesis and characterisation of SNS-032-BODIPY
SNS-032-BODIPY was synthesized using SNS-032 (Selleck Chemicals) and BDP-FL-NHS-ester (Lumiprobe, Hannover, Germany) (Supplementary Figure S7A) . All other reagents and solvents were purchased from Fisher Scientific (Loughborough, UK). NMR spectra were collected on a JEOL 400 MHz. HRMS were collected on a Bruker MicroTOFQ spectrometer by direct injection with a MeOH/HCOOH matrix. Excitation and emission spectra were collected on an Edinburgh Instruments FS-5 spectrofluorimeter. HPLC traces were collected on a Dionex U3000 HPLC apparatus.
To 7.68 mg (2.02 × 10 -2 mmol) of SNS-032 chloroform (1.3 mL) was added and the mixture sonicated until dossolution. BDP-FL NHS ester (purchased from Lumiprobe; 8.09 mg, 2.08 × 10 -2 mmol) was also dissolved in chloroform (1.3mL) and sonicated to ensure dissolution. The SNS-032 mixture was added to BDP-FL and the resulting sample was sonicated for 1 h. Reaction was monitored using thin-layer chromatography (dichloromethane: methanol -4:0.1; product rf: 0.21). Reaction mixture was concentrated and then purified by preparative TLC using the above noted eluent. The adsorbed product band on the silica plate was scraped, isolated and rinsed repeatedly with acetonitrile to extract the product yielding 9.0 mg (1.38 × 10 -2 mmol; 68%). Purity was confirmed by reverse-phase HPLC ( Figure 7B-7E 
Cell lines
The MYCN-amplified neuroblastoma cell line UKF-NB-3 was established from a stage 4 neuroblastoma patient [44] . SHEP cells [45] were kindly provided by Dr. Angelika Eggert (Universität Duisburg-Essen, Germany). Neuroblastoma cell lines were adapted to growth in the presence of anti-cancer drugs by continuous exposure to increasing drug concentrations as described previously [19, 47, 49] . All neuroblastoma cell lines with acquired drug resistance were derived from the resistant cancer cell line (RCCL) collection. The corresponding IC50 values for the parental cells and their drug-resistant sub-lines were provided previously [19, 50] . All cells were propagated in IMDM supplemented with 10 % fetal calf serum (FCS), 100 IU/ml penicillin, and 100 µg/ml streptomycin at 37°C. Cells were routinely tested for mycoplasma contamination and authenticated by short tandem repeat profiling.
UKF-NB-3 cells were transduced with lentiviral vectors encoding for ABCB1 (also known as MDR1 or P-glycoprotein) or ABCG2 (also known as BCRP) as described previously [50, 51] using the Lentiviral Gene Ontology (LeGO) vector technology [52] (www.lentigovectors.de).
Viability assay
Cell viability was tested either by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye reduction assay after 120 h incubation modified as described previously [47, 50] .
Determination of ABCB1, ABCG2, and ABCC1 expression
The ABC-transporters ABCB1, ABCC1, and ABCG2 were detected by flow cytometry as described previously [51] using specific primary antibodies against ABCB1 (Alexis Biochemicals via AXXORA Deutschland, Lörrach, Germany), ABCC1, and ABCG2 (Kamiya Biomedical Company, Seattle, Washington) and secondary phycoerythrin(PE)-labelled goat anti-mouse antibody (PE, R&D Systems, Wiesbaden, Germany).
RNA interference experiments
Synthetic siRNAoligonucletides targeting CDK7, CDK9, ABCC1, or ABCB1 (ONTARGETplusSMARTpoolsiRNAs) were purchased from Dharmacon (Lafayette, CO, USA). The non-targeting siRNA ON-TARGETplusSMARTpool (Dharmacon) was used as negative control. Transfections were performed using the Neon TM Transfection System (Invitrogen, Darmstadt, Germany) according to the manufacturer´s protocol. UKF-NB-3 cells or UKF-NB-3 r SNS-032 300nM cells were grown to about 60-80% confluence, trypsinized and 2 × 10 6 cells were re-suspended in 200 µl of resuspension buffer containing 2.5 µM siRNA. Electroporation was performed in a pipette tip chamber with previously optimized adjustments (voltage 1400, width 20, 2 pulses). After electroporation, the cells were transferred into fibronectin (100 μg/ml)-coated well plates containing pre-warmed IMDM plus 10% FCS.
Western blot
Cells were lysed in Triton X-sample buffer and separated by SDS-PAGE. Proteins were detected using specific antibodies directed against β-actin (BioVision via BioCat GmbH, Heidelberg, Germany), ABCC1, ABCG2 (both from Santa Cruz Biotechnology, Heidelberg, Germany), ABCB1, XIAP, Mcl-1, CDK7, CDK9 (all from Cell Signaling via New England Biolabs, Frankfurt am Main, Germany), RNA polymerase II, Ser2-phosphorylated RNA polymerase II, Ser5-phosphorylated RNA polymerase II (all from Abcam, Cambridge, UK), and survivin (R&D Systems, Wiesbaden, Germany). Protein bands were visualized by enhanced chemiluminescence using a commercially available kit (Thermo Scientific, Schwerte, Germany).
Flow cytometry
Cells were incubated with SNS-032-BODIPY for 45 min at 37°C. Then, the cells were washed twice with PBS before fresh medium was added. The cellular fluorescence was analysed after a further 120 minutes using a FACS Canto (BD Biosciences, Heidelberg, Germany) using the FL1 channel. In verapamil-treated cells, verapamil was continuously present throughout the experiments including a pre-incubation period of 30 minutes at 37°C prior to the addition of SNS-032-BODIPY.
RNA synthesis assay
Detection of global RNA synthesis was performed as previously described [19] using the Click-iT ® RNA HCS Assay (Invitrogen, Darmstadt, Germany).
